Hesperetin-Cu(II) complex as potential α-amylase and α-glucosidase inhibitor: Inhibition mechanism and molecular docking
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · 2023-04 · 290 · 122301
DOI: 10.1016/j.saa.2022.122301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2023-04. Verfasst von Xi Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China; Jiangxi Biotech Vocational College, Nanchang 330200…. Hauptthemen laut MEDLINE: Glycoside Hydrolase Inhibitors, Diabetes Mellitus. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province, State Key Laboratory of Food Science and Technology, Nanchang University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Inhibition of α-amylase and α-glucosidase activity is an effective way for controlling postprandial blood glucose-related diabetes. The study found that hesperetin-Cu(II) complex (Hsp-Cu(II)) exhibited a stronger inhibitory ability on α-amylase and α-glucosidase compared to hesperetin (Hsp), with smaller IC50 values of Hsp-Cu(II) (60.3 ± 0.9 µM for α-amylase; 1.25 ± 0.03 µM for α-glucosidase) than Hsp (115.6 ± 1.1 µM for α-amylase; 55.2 ± 0.1 µM for α-glucosidase). Interestingly, Hsp-Cu(II) and acarbose exerted a synergistic effect on inhibition of α-glucosidase. The binding affinities of Hsp-Cu(II) to α-amylase and α-glucosidase were strong with the Ka values (binding constant) in the magnitude order of 105, which was 9 times larger than Hsp. After interacting, Hsp-Cu(II) reduced α-helix contents of α-amylase and α-glucosidase, resulting in a looser conformation of these two enzymes. Molecular simulations manifested that Hsp-Cu(II) bound to the active center of enzymes driven by hydrogen bonds and interacted with the key catalytic amino acids (α-amylase: Gln63, Asp300 and His305; α-glucosidase: Tyr158, Asp215, Glu277 and Glu411), altering the conformation of enzymes, blocking the entrance of substrates, ultimately reducing the activities of α-glucosidase and α-amylase. This study has demonstrated that Hsp-Cu(II) may be a promising candidate of functional nutritional additive and medicine for the prevention of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China; Jiangxi Biotech Vocational College, Nanchang 330200, China.
- State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China.
- State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China. Electronic address: gwzhang@ncu.edu.cn.
Förderung
- Natural Science Foundation of Jiangxi Province
- State Key Laboratory of Food Science and Technology, Nanchang University
- National Natural Science Foundation of China
Zitieren
APA
Peng, X., Liu, K., Hu, X., Gong, D., & Zhang, G. (2023). Hesperetin-Cu(II) complex as potential α-amylase and α-glucosidase inhibitor: Inhibition mechanism and molecular docking. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 290, 122301. https://doi.org/10.1016/j.saa.2022.122301
Vancouver
Peng X, Liu K, Hu X, Gong D, Zhang G. Hesperetin-Cu(II) complex as potential α-amylase and α-glucosidase inhibitor: Inhibition mechanism and molecular docking. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2023;290:122301. doi:10.1016/j.saa.2022.122301
BibTeX
@article{Peng2023,
author = {Peng, Xi and Liu, Kai and Hu, Xing and Gong, Deming and Zhang, Guowen},
title = {Hesperetin-Cu(II) complex as potential α-amylase and α-glucosidase inhibitor: Inhibition mechanism and molecular docking},
journal = {Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy},
year = {2023},
volume = {290},
pages = {122301},
doi = {10.1016/j.saa.2022.122301}
}
EUVIMED